About Flex Pharma (NASDAQ:FLKS)
Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:FLKS
- CUSIP: N/A
- Web: www.flex-pharma.com
- Market Cap: $60.03 million
- Outstanding Shares: 17,285,000
- 50 Day Moving Avg: $3.42
- 200 Day Moving Avg: $3.42
- 52 Week Range: $3.01 - $8.43
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.57
- P/E Growth: 0.00
- Annual Revenue: $1.48 million
- Price / Sales: 39.01
- Book Value: $2.58 per share
- Price / Book: 1.29
- EBITDA: ($35,580,000.00)
- Net Margins: -2,410.97%
- Return on Equity: -64.15%
- Return on Assets: -59.78%
- Current Ratio: 9.75%
- Quick Ratio: 9.62%
- Average Volume: 23,934 shs.
- Beta: 3.3
- Short Ratio: 1.22
Frequently Asked Questions for Flex Pharma (NASDAQ:FLKS)
What is Flex Pharma's stock symbol?
Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."
How were Flex Pharma's earnings last quarter?
Flex Pharma, Inc. (NASDAQ:FLKS) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.51) EPS for the quarter, beating the Zacks' consensus estimate of ($0.63) by $0.12. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $0.46 million. Flex Pharma had a negative return on equity of 64.15% and a negative net margin of 2,410.97%. View Flex Pharma's Earnings History.
When will Flex Pharma make its next earnings announcement?
Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2017?
5 brokerages have issued 1-year target prices for Flex Pharma's shares. Their forecasts range from $8.00 to $14.00. On average, they anticipate Flex Pharma's stock price to reach $11.00 in the next twelve months. View Analyst Ratings for Flex Pharma.
What are analysts saying about Flex Pharma stock?
Here are some recent quotes from research analysts about Flex Pharma stock:
- 1. According to Zacks Investment Research, "Flex Pharma, Inc. is a biotechnology company. The Company is involved in developing treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Flex Pharma, Inc. is headquartered in Boston, Massachusetts. " (10/10/2017)
- 2. Cantor Fitzgerald analysts commented, "Phase II COMMEND trial of FLX-787 is expected to have data in 2018 in ALS." (9/25/2017)
Who are some of Flex Pharma's key competitors?
Some companies that are related to Flex Pharma include Axsome Therapeutics (AXSM), Synthetic Biologics (SYN), Dicerna Pharmaceuticals (DRNA), DURECT (DRRX), Summit Therapeutics PLC (SUMM), ProQR Therapeutics N.V. (PRQR), Intec Pharma (NTEC), Motif Bio PLC (MTFB), Trevena (TRVN), Otonomy (OTIC), Zafgen (ZFGN), Gemphire Therapeutics (GEMP), MEI Pharma (MEIP), Galmed Pharmaceuticals (GLMD), Affimed N.V. (AFMD), Versartis (VSAR), AcelRx Pharmaceuticals (ACRX) and Ophthotech Corporation (OPHT).
Who are Flex Pharma's key executives?
Flex Pharma's management team includes the folowing people:
- Christoph H. Westphal M.D. Ph.D., Chairman of the Board
- William K. McVicar Ph.D., President, Chief Executive Officer, Director
- John McCabe, Chief Financial Officer, Treasurer
- Kathie Lindemann, Chief Operating Officer
- Jennifer Cermak Ph.D., Vice President - Research & Development
- Robert Hadfield Ph.D., General Counsel, Secretary
- Elizabeth Woo M.D. Ph.D., Senior Vice President, Investor Relations and Corporate Communications
- Thomas C. Wessel M.D. Ph.D., Chief Medical Officer
- Jeffrey D. Capello, Director
- Roderick Mackinnon M.D, Director
When did Flex Pharma IPO?
(FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.
How do I buy Flex Pharma stock?
Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flex Pharma's stock price today?
MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Flex Pharma stock can currently be purchased for approximately $3.34.
Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 4 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.80)|
|Consensus Price Target: ||$11.00 (229.34% upside)|Consensus Price Target History for Flex Pharma (NASDAQ:FLKS)
Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/25/2017||Cantor Fitzgerald||Reiterated Rating||Hold||$10.00||Medium|
|9/7/2017||Roth Capital||Initiated Coverage||Buy||$14.00||Low|
|5/4/2017||Jefferies Group LLC||Lower Price Target||Buy||$9.00 -> $8.00||High|
|3/8/2017||Piper Jaffray Companies||Set Price Target||Buy||$12.00||Low|
|11/3/2016||JMP Securities||Reiterated Rating||Buy||N/A|
|10/15/2016||HC Wainwright||Reiterated Rating||Buy||$40.00||N/A|
Earnings History for Flex Pharma (NASDAQ:FLKS)Earnings History by Quarter for Flex Pharma (NASDAQ FLKS)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||($0.63)||($0.51)||$0.46 million||$0.34 million||View||Listen|
|5/3/2017||Q1 2017||($0.62)||($0.49)||$0.38 million||$0.24 million||View||Listen|
|3/8/2017||Q4 2016||($0.84)||($0.48)||$0.09 million||$0.30 million||View||Listen|
|11/2/2016||Q316||($0.72)||($0.65)||$0.15 million||$0.60 million||View||Listen|
|8/3/2016||Q216||($0.67)||($0.71)||$0.01 million||$0.11 million||View||Listen|
Earnings Estimates for Flex Pharma (NASDAQ:FLKS)
2017 EPS Consensus Estimate: ($2.03)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Flex Pharma (NASDAQ:FLKS)
Insider Ownership Percentage: 45.36%Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)
Institutional Ownership Percentage: 27.74%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/8/2016||Christoph H Westphal||Insider||Buy||7,000||$7.31||$51,170.00|| |
|11/7/2016||Christoph H Westphal||Insider||Buy||8,870||$5.70||$50,559.00|| |
|11/7/2016||John P Mccabe||VP||Buy||1,650||$6.01||$9,916.50|| |
|6/23/2016||Christoph H Westphal||CEO||Buy||2,700||$11.28||$30,456.00|| |
|6/22/2016||Christoph H Westphal||CEO||Buy||5,700||$11.05||$62,985.00|| |
|6/21/2016||Christoph H Westphal||CEO||Buy||2,800||$11.07||$30,996.00|| |
|6/20/2016||Christoph H Westphal||CEO||Buy||6,000||$11.18||$67,080.00|| |
|6/16/2016||Christoph H Westphal||CEO||Buy||5,800||$11.17||$64,786.00|| |
|6/14/2016||Christoph H Westphal||CEO||Buy||5,900||$11.54||$68,086.00|| |
|6/10/2016||Christoph H Westphal||CEO||Buy||6,000||$11.94||$71,640.00|| |
|6/8/2016||Christoph H Westphal||CEO||Buy||5,900||$12.25||$72,275.00|| |
|6/6/2016||Christoph H Westphal||CEO||Buy||6,000||$12.56||$75,360.00|| |
|6/2/2016||Christoph H Westphal||CEO||Buy||10,000||$12.99||$129,900.00|| |
|5/31/2016||Christoph H Westphal||CEO||Buy||22,300||$12.68||$282,764.00|| |
|5/26/2016||Christoph H Westphal||CEO||Buy||28,600||$12.84||$367,224.00|| |
|5/24/2016||Christoph H Westphal||CEO||Buy||30,334||$12.42||$376,748.28|| |
|5/20/2016||Christoph H Westphal||CEO||Buy||7,914||$11.06||$87,528.84|| |
|5/18/2016||Christoph H Westphal||CEO||Buy||33,400||$11.10||$370,740.00|| |
|5/16/2016||Christoph H Westphal||CEO||Buy||15,469||$10.25||$158,557.25|| |
|5/12/2016||Christoph H Westphal||CEO||Buy||30,217||$10.12||$305,796.04|| |
|5/10/2016||Christoph H Westphal||CEO||Buy||30,109||$9.94||$299,283.46|| |
|3/24/2016||Christoph H Westphal||CEO||Buy||49,563||$11.06||$548,166.78|| |
|3/22/2016||Christoph H Westphal||CEO||Buy||23,951||$11.78||$282,142.78|| |
|3/21/2016||Christoph H Westphal||CEO||Buy||48,058||$11.74||$564,200.92|| |
|3/18/2016||Christoph H Westphal||CEO||Buy||37,574||$11.00||$413,314.00|| |
|3/16/2016||Christoph H Westphal||CEO||Buy||38,379||$10.23||$392,617.17|| |
|3/15/2016||Michelle Stacy||Director||Buy||2,585||$9.63||$24,893.55|| |
|3/14/2016||Thomas Wessel||Insider||Buy||20,000||$7.94||$158,800.00|| |
|3/11/2016||Christoph H Westphal||CEO||Buy||89,680||$7.00||$627,760.00|| |
|3/11/2016||Roderick Mackinnon||Director||Buy||10,000||$7.03||$70,300.00|| |
|12/14/2015||Christoph H Westphal||CEO||Buy||927||$12.01||$11,133.27|| |
|12/7/2015||Christoph H Westphal||CEO||Buy||907||$12.02||$10,902.14|| |
|11/19/2015||Marc D Kozin||Director||Buy||4,500||$11.38||$51,210.00|| |
|11/16/2015||Christoph H Westphal||CEO||Buy||1,001||$10.78||$10,790.78|| |
|11/9/2015||Christoph H Westphal||CEO||Buy||1,000||$11.03||$11,030.00|| |
|10/26/2015||Christoph H Westphal||CEO||Buy||1,043||$10.55||$11,003.65|| |
|10/19/2015||Christoph H Westphal||CEO||Buy||1,018||$10.61||$10,800.98|| |
|9/28/2015||Christoph H Westphal||CEO||Buy||924||$11.18||$10,330.32|| |
|3/30/2015||Christoph H Westphal||CEO||Buy||272||$20.52||$5,581.44|| |
Headline Trends for Flex Pharma (NASDAQ:FLKS)
Latest Headlines for Flex Pharma (NASDAQ:FLKS)
Loading headlines, please wait.
Flex Pharma (FLKS) Chart for Sunday, October, 22, 2017